Quick Answer
CRESCENT BIOPHARMA, INC. reported Research And Development Expense of $138.09 million for the year ending 2025.
- CRESCENT BIOPHARMA, INC. showed an increase of +868.4% in Research And Development Expense from 2024 to 2025.
- This data is from CRESCENT BIOPHARMA, INC.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 14 years of available data (2012 to 2025), CRESCENT BIOPHARMA, INC.'s Research And Development Expense has grown by 1,363.0%.
- Historical annual values: Fiscal year 2025: $138.09 million | Fiscal year 2024: $14.26 million | Fiscal year 2023: $20.07 million | Fiscal year 2022: $28.39 million | Fiscal year 2021: $47.49 million | Fiscal year 2020: $44.93 million | Fiscal year 2019: $47.03 million | Fiscal year 2018: $40.09 million | Fiscal year 2017: $24.10 million | Fiscal year 2016: $23.28 million | Fiscal year 2015: $25.05 million | Fiscal year 2014: $19.57 million | Fiscal year 2013: $11.70 million | Fiscal year 2012: $9.44 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: